Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients (COPD Readmit)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03647462|
Recruitment Status : Not yet recruiting
First Posted : August 27, 2018
Last Update Posted : January 9, 2019
|Condition or disease||Intervention/treatment||Phase|
|Obstructive Sleep Apnea Chronic Obstructive Pulmonary Disease||Device: Continuous Positive Airway Pressure||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Chronic Obstructive Pulmonary Disease Patients: the COPD Readmit Clinical Trial|
|Estimated Study Start Date :||February 28, 2019|
|Estimated Primary Completion Date :||February 28, 2020|
|Estimated Study Completion Date :||April 30, 2020|
Experimental: CPAP Intervention Pathway
Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.
The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
Device: Continuous Positive Airway Pressure
CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
No Intervention: Usual Care Pathway
Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
- Hospital readmission and mortality rates [ Time Frame: 30 days ]Number of occasions patient has been admitted to the hospital and number of patients who have died
- Clinic and urgent care visits [ Time Frame: 30 days ]Appointments with any medical providers (sleep, cardiac, primary) at a clinic or urgent care facility
- Off work orders [ Time Frame: 30 days ]Note from provider ordering/requesting patient to be dismissed from work for medical reasons (sick, injured, etc.)
- STOP BANG [ Time Frame: 30 days ]Snoring, tiredness, observed apnea, blood pressure, body mass index, age, neck circumference, and gender (STOP BANG) is the name of a OSA screening questionnaire. Questionnaire contains 8 "Yes/No" questions and the number of "Yes" answers provide a total score (range 0-8). Patients that answer "Yes" to 3-4 questions are typically considered to be at intermediate risk of OSA.
- Epworth Sleepiness Scale (ESS) [ Time Frame: 30 days ]Epworth Sleepiness Scale measures degree of sleepiness. 8 scenarios are described and the responder indicates their likelihood of dozing unintentionally (range 0-3). A total of the scores are added (range 0-24) and typically scores of at least 11 indicate excessive sleepiness.
- Patient Reported Outcome Measurement Information System (PROMIS) [ Time Frame: 30 days ]Patient Reported Outcome Measurement Information System is a 10 item questionnaire that measures physical, mental, and social health in adults. It can be used on the general population and patients with chronic conditions. Patients rate their health based on a severity scale of 1-5 (1 indicates poor health) and the scoring system allows each question/item to be evaluated separately.
- Chronic Obstructive Pulmonary Disease Assessment Tool (CAT) [ Time Frame: 30 days ]Chronic Obstructive Pulmonary Disease (COPD) Assessment Tool is a questionnaire that measures the impact the disease has on patients well being and daily life. There are 8 questions that ask about common symptoms COPD patients experience and the patient indicates their severity (range 0-5). A total of the scores are added (range 0-40) and scores of at least 30 indicate that their COPD has a very high level of impact on their daily lives.
- Comparing inpatient portable monitor versus 30-day follow up portable monitor results in usual care group [ Time Frame: 30 days ]Evaluating the change of sleep diagnostic test results from the hospital to 1-month after being discharged (only for patients enrolled in the Usual Care pathway)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03647462
|Contact: Dennis Hwang, MDemail@example.com|
|Contact: Jessica Arguelles, BSfirstname.lastname@example.org|
|Principal Investigator:||Dennis Hwang, MD||Kaiser Permanente, Fontana Medical Center|